pepFastX™ Mouse Anti-VACV WR L1R (AVVDNKLKI) Monoclonal Antibody (22410YF)



  • Datasheet

  • MSDS

  • COA

    Certificate of Analysis Lookup

    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

    Lot Number

  • Tech Support

Cat#: VRH-22410F

pepFastX™ Mouse Anti-VACV WR L1R (AVVDNKLKI) Monoclonal Antibody (22410YF)

This mouse monoclonal antibody 22410YF is generated from premade hybridoma library, and specific for Vaccinia virus WR L1R (AA 120-128): AVVDNKLKI. For any additional requirments, please specify and submit an inquiry for assistance.

Made to Order Requirements







0.1 mg

0.2 mg

0.5 mg

1 mg

Your choose infomation:


(Note: Please select the requirements to fit you project. If you have any other requirements, please specify. If no specific requirements, you don't need to select any button.)

  • Antibody Testing Data
  • Target Published Figures
  • Product Overview
  • Product Properties
  • Applications

Product Overview

Target : L1R
Specificity : VACV WR
Clone : 22410YF
Host Species : Mouse
Antibody Isotype : IgG
Species Reactivity : Vaccinia virus

Product Properties

Immunogen : Synthetic peptide corresponding to amino acid sequence: AVVDNKLKI.
Purity : >95%
Purification : Protein A or G affinity chromatography
Concentration : Lot specific


Application : ELISA
Application Notes : The antibody is screened by ELISA using the synthetic peptide that corresponds to amino acids sequence (AVVDNKLKI) as the capture antigen. Additional applications have not been validated. It is recommended that the end users validate other applications and determine optimal concentrations/dilution under their experimental conditions.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.


Google Scholar



L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccines.


Google Scholar



  • (Verified Customer)

    I ordered the Mouse Anti-VACV WR L1R (AVVDNKLKI) Monoclonal Antibody (22410YF), and will test it in Western Blot analysis with L1R antigen. Hope it will work well.

  • (Verified Customer)

    The purity of this VACV WR L1R antibody is verified to be>95% as determined by SDS-PAGE gel.

(Verified Customer)

I would like to know the peptide seq to which this antibody recognizes in the VACV WR L1R protein.

(Creative Biolabs Scientific Support)

The antigen of this antibody used for screening is peptide - AVVDNKLKI.

(Verified Customer)

Dear sir,
We're interested in VRH-22410F. Please help us confirm if this antibody can be used for neutralization assays?
Wang, Yiwei

(Creative Biolabs Scientific Support)

Thank you for contacting us. We have not tested the neutralization capability of this antibody. I am sorry for not being able to provide you any useful information this time. Please don't hesitate to contact us if you need any further advice or information in other aspects.

Target Research Highlights

The author constructed a recombinant vaccinia virus (VACV) (vL1Ri) which can express L1, and demonstrated that L1 protein of VACV is essential for virus assembly, cell entry and membrane fusion. Moreover, L1 was proved to be interacted with the entry/fusion complex (EFC) as an another component.


Bisht, Himani, Andrea S. Weisberg, and Bernard Moss. "Vaccinia virus L1 protein is required for cell entry and membrane fusion." Journal of virology 82.17 (2008): 8687-8694.

Google Scholar



Target Research Highlights

This article analyzed the roles of L1 and A28 of vaccinia virus (VACV) for cellular entry. The results indicated that a soluble, truncated form of L1 serves as receptor binding proteins (RBP) independently of glycosaminoglycans (GAGs).


Foo, Chwan Hong, et al. "Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans." Virology 385.2 (2009): 368-382.

Google Scholar



Inquiry Basket